ALTO NEUROSCIENCE INC (ANRO)
US02157Q1094 - Common Stock
ANRO gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 192 industry peers in the Pharmaceuticals industry. While ANRO seems to be doing ok healthwise, there are quite some concerns on its profitability. ANRO has a expensive valuation and it also scores bad on growth.
1. Profitability
1.1 Basic Checks
In the past year ANRO has reported negative net income.
ANRO had a negative operating cash flow in the past year.
1.2 Ratios
With a Return On Assets value of -29.98%, ANRO perfoms like the industry average, outperforming 55.43% of the companies in the same industry.
ANRO has a better Return On Equity (-34.81%) than 64.67% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -29.98% | ||
| ROE | -34.81% | ||
| ROIC | N/A |
ROA(3y)-42.77%
ROA(5y)N/A
ROE(3y)-56.56%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
ANRO does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
Compared to 1 year ago, ANRO has about the same amount of shares outstanding.
The debt/assets ratio for ANRO has been reduced compared to a year ago.
2.2 Solvency
An Altman-Z score of 1.88 indicates that ANRO is not a great score, but indicates only limited risk for bankruptcy at the moment.
ANRO has a Altman-Z score of 1.88. This is in the better half of the industry: ANRO outperforms 66.85% of its industry peers.
ANRO has a Debt/Equity ratio of 0.05. This is a healthy value indicating a solid balance between debt and equity.
ANRO's Debt to Equity ratio of 0.05 is in line compared to the rest of the industry. ANRO outperforms 51.09% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.05 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 1.88 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
A Current Ratio of 13.09 indicates that ANRO has no problem at all paying its short term obligations.
ANRO has a better Current ratio (13.09) than 88.04% of its industry peers.
ANRO has a Quick Ratio of 13.09. This indicates that ANRO is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 13.09, ANRO belongs to the top of the industry, outperforming 88.04% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 13.09 | ||
| Quick Ratio | 13.09 |
3. Growth
3.1 Past
ANRO shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -31.44%.
EPS 1Y (TTM)-31.44%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%36.54%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
Based on estimates for the next years, ANRO will show a quite strong growth in Earnings Per Share. The EPS will grow by 12.33% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y44.72%
EPS Next 2Y20.81%
EPS Next 3Y12.33%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for ANRO. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ANRO. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as ANRO's earnings are expected to grow with 12.33% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y20.81%
EPS Next 3Y12.33%
5. Dividend
5.1 Amount
ANRO does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
ALTO NEUROSCIENCE INC
NYSE:ANRO (1/3/2025, 8:19:56 PM)
After market: 4.56 -0.05 (-1.08%)4.61
+0.23 (+5.25%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners70.78%
Inst Owner Change0%
Ins Owners7.51%
Ins Owner Change0%
Market Cap124.33M
Analysts86.15
Price Target12.04 (161.17%)
Short Float %16.32%
Short Ratio4.9
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)9.58%
Min EPS beat(2)6.96%
Max EPS beat(2)12.2%
EPS beat(4)2
Avg EPS beat(4)-99.55%
Min EPS beat(4)-356.11%
Max EPS beat(4)12.2%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)15.12%
PT rev (3m)-62.54%
EPS NQ rev (1m)0%
EPS NQ rev (3m)10.15%
EPS NY rev (1m)-0.26%
EPS NY rev (3m)0.7%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | N/A | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 0.75 | ||
| P/tB | 0.75 | ||
| EV/EBITDA | N/A |
EPS(TTM)-9.75
EYN/A
EPS(NY)-2.58
Fwd EYN/A
FCF(TTM)-1.77
FCFYN/A
OCF(TTM)-1.7
OCFYN/A
SpS0
BVpS6.12
TBVpS6.12
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -29.98% | ||
| ROE | -34.81% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-42.77%
ROA(5y)N/A
ROE(3y)-56.56%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.05 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 453.07% | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 13.09 | ||
| Quick Ratio | 13.09 | ||
| Altman-Z | 1.88 |
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)269.67%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-31.44%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%36.54%
EPS Next Y44.72%
EPS Next 2Y20.81%
EPS Next 3Y12.33%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-29.52%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-60.55%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-64.01%
OCF growth 3YN/A
OCF growth 5YN/A